Translational Medicine Organization
Affiliation
organization within
Research
administers grant
- AAMC Improving Clinical and Public Health Outcomes through National Partnerships to Prevent and Control Emerging and Re-Emerging Infectious Disease Threats
- Analysis of Glycomic Regulators in Melanoma Progression
- Analysis of galectin-8 and its ligands in melanoma progression
- Analysis of novel biomarkers of melanoma metastasis
- Analysis of vascular Galectin-9 as an immunomodulator of B-cell activity
- Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program - Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma: A Trial of the AIDS Malignancy Consortium (AMC)
- Cell type-directed Tim-3 targeting in melanoma
- FY2021-2031: Alzheimer's Research Using Exablate Neuro Focused Ultrasound - Baptist 1.5M
- Forging Translational Glycobiologists: Intermeshing Glycoscience Training and Clinical Education
- Forging Translational Glycobiologists: Intermeshing Glycoscience Training and Clinical Education: Chandler KB
- Functional Analysis of Human Endothelial Cell Galectin-9 on Human B cells
- Functional analysis of a novel integrin-dependent metastasis pathway in melanoma
- Glycomics Laboratory for the Development of Ovarian Cancer Biomarkers
- Harnessing E-selectin ligands to Target Tumors of the Central Nervous System
- Head and Neck Cancer Mucinomics
- Hypoxia as a driver of the metastatic melanoma glycome and its immune evasion capacity
- Hypoxia dependent GCNT2 downregulation and immune modulation in metastatic melanoma
- Impact of Human Melanoma Glycome on Immune Evasion
- Infectious Diseases Society of America (IDSA) Foundation Student Interest Group Grant
- Janssen 2024 SODEP scholar selections
- Novel platform linking cancer-specific glycosylation with cell signaling outcomes
- Sequential Retinoic Acid Presentation in T Cells
- Targeting the Melanoma Glycome to Improve Immune Checkpoint Inhibitor Therapy
- The metastasis-suppressive function of intracellular galectin-3 in melanoma
- Tumor-Derived Immunoglobulin Driven Resistance to anti-PD1/PDL1 Axis Therapy